Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating
patients with newly diagnosed triple negative breast cancer that is limited to the breast and
possibly to the nearby lymph nodes (locally advanced). This treatment study is linked to
NCI-2015-00191 protocol, which uses a baseline biopsy to determine the neoadjuvant therapy
that matches the sub-type of triple negative breast cancer (TNBC). Immunotherapy with
panitumumab, may induce changes in body's immune system and may interfere with the ability of
tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving
panitumumab, carboplatin and paclitaxel before surgery may be an effective treatment for
breast cancer by making the tumor smaller and reducing the amount of normal tissue that needs
to be removed.